Dolutegravir (DTG) is an integrase strand transfer inhibitor indicated for the treatment of human immunodeficiency virus (HIV) type-1 infection. This study aims to describe the prevalence of exposure to DTG-containing regimens among women of child-bearing age living with HIV and among pregnant women in the Sentinel System. Using the Sentinel Distributed Database (SDD), the prevalence of DTG use was examined (using National Drug Codes) among women of childbearing age (15 to 49 years old) with an HIV diagnosis and among women aged 15 to 49 years old with live birth deliveries from August 2013 through March 2018.
The following presentation was presented at the 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management in 2019.
James Phillip Trinidad, Talia Menzin, Elizabeth Dee, Monique Falconer, Mayura Shinde